Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL
Season 5, Episode 25, Jul 19, 2021, 08:24 PM
Share
Subscribe
Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.